Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

655
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
655
Peripheral Artery Disease IV: Nursing Management01:26

Peripheral Artery Disease IV: Nursing Management

702
 The nursing management of a patient with peripheral artery disease (PAD) begins with a thorough assessment of the patient’s health history and clinical manifestations.AssessmentHealth History: Evaluate the patient’s history of hypertension, hyperlipidemia, family history of cardiovascular issues, and lifestyle factors such as dietary patterns, smoking, and physical activity.Physical Examination:Assess the affected extremity for decreased or absent peripheral pulses,...
702
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

659
Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
659
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

613
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
613
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation01:21

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

764
Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
764
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

615
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
615

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Breakthrough drugs in the treatment of hypertension-related disease.

Hypertension research : official journal of the Japanese Society of Hypertension·2026
Same author

Fibroblast activation protein protects the ischemic brain through regulation of post-ischemic inflammation.

Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism·2026
Same author

The blood pressure-lowering effect of an anti-soluble epoxide hydrolase vaccine in angiotensin II-induced hypertension in mice.

Hypertension research : official journal of the Japanese Society of Hypertension·2026
Same author

A RANKL-derived Peptide Inhibits RSPO3-LGR4-Wnt Signaling and Lung Adenocarcinoma in Mice.

Anticancer research·2026
Same author

Needle-Free Injection Enhances the Immunogenicity and Antitumor Efficacy of Whole-Cell Tumor Vaccines.

Vaccines·2026
Same author

Changes in blood pressure following the relocation of individuals to well-insulated and well-ventilated apartments building.

Hypertension research : official journal of the Japanese Society of Hypertension·2026

Related Experiment Video

Updated: Apr 30, 2026

Osmotic Drug Delivery to Ischemic Hindlimbs and Perfusion of Vasculature with Microfil for Micro-Computed Tomography Imaging
10:50

Osmotic Drug Delivery to Ischemic Hindlimbs and Perfusion of Vasculature with Microfil for Micro-Computed Tomography Imaging

Published on: June 29, 2013

11.6K

Gene therapy for peripheral arterial disease.

Munehisa Shimamura1, Hironori Nakagami, Yoshiaki Taniyama

  • 1Osaka University, Kanazawa University and Hamamatsu University School of Medicine, United Graduate School of Child Development, Division of Vascular Medicine and Epigenetics, Department of Child Development , Suita , Japan.

Expert Opinion on Biological Therapy
|April 29, 2014
PubMed
Summary

Gene therapy shows promise for critical limb ischemia (CLI) by promoting angiogenesis. While safe in early trials, further research and improved delivery methods are needed to confirm its effectiveness in treating CLI symptoms.

Keywords:
VEGFangiogenesiscell-based therapyfibroblast growth factorgene therapyhepatocyte growth factor

More Related Videos

Preclinical Model of Hind Limb Ischemia in Diabetic Rabbits
07:34

Preclinical Model of Hind Limb Ischemia in Diabetic Rabbits

Published on: June 2, 2019

9.4K
Embryonic Stem Cell-Derived Endothelial Cells for Treatment of Hindlimb Ischemia
09:11

Embryonic Stem Cell-Derived Endothelial Cells for Treatment of Hindlimb Ischemia

Published on: January 23, 2009

11.1K

Related Experiment Videos

Last Updated: Apr 30, 2026

Osmotic Drug Delivery to Ischemic Hindlimbs and Perfusion of Vasculature with Microfil for Micro-Computed Tomography Imaging
10:50

Osmotic Drug Delivery to Ischemic Hindlimbs and Perfusion of Vasculature with Microfil for Micro-Computed Tomography Imaging

Published on: June 29, 2013

11.6K
Preclinical Model of Hind Limb Ischemia in Diabetic Rabbits
07:34

Preclinical Model of Hind Limb Ischemia in Diabetic Rabbits

Published on: June 2, 2019

9.4K
Embryonic Stem Cell-Derived Endothelial Cells for Treatment of Hindlimb Ischemia
09:11

Embryonic Stem Cell-Derived Endothelial Cells for Treatment of Hindlimb Ischemia

Published on: January 23, 2009

11.1K

Area of Science:

  • Vascular Biology and Regenerative Medicine
  • Gene Therapy Applications
  • Peripheral Artery Disease Treatment

Background:

  • Gene therapy utilizing pro-angiogenic factors like VEGF, FGF, and HGF is being explored for critical limb ischemia (CLI).
  • Early clinical trials (Phase I/II) indicate safety and potential symptomatic improvement in CLI patients.
  • Limitations in transgene expression with naked plasmid DNA (pDNA) have been observed in Phase III trials.

Purpose of the Study:

  • To review existing research on VEGF, FGF, and HGF gene therapies for CLI.
  • To examine adjunctive therapies and advanced gene transfer techniques for enhanced efficacy.
  • To assess the current status and future directions of gene therapy for CLI.

Main Methods:

  • Comprehensive review of published basic research and clinical trials.
  • Analysis of studies investigating specific growth factors (VEGF, FGF, HGF) for CLI.
  • Evaluation of novel gene transfer systems and combination gene therapies.

Main Results:

  • Clinical studies confirm the safety profile of gene therapy for limb ischemia.
  • Effectiveness of current gene therapy approaches for CLI remains undetermined.
  • Limited transgene expression with naked pDNA necessitates improved delivery systems.

Conclusions:

  • Gene therapy is a safe approach for limb ischemia, but efficacy requires further validation.
  • Development of enhanced gene transfer techniques is crucial for successful CLI treatment.
  • Larger clinical studies are essential to confirm the beneficial effects of gene therapy in CLI patients.